Abstract | BACKGROUND AND OBJECTIVE: METHODS: Two hundred seventy two anemic CKD patients not on dialysis treated with C.E.R.A. were included in this retrospective, observational, multicentric study during 2010. Demographical characteristics, analytical parameters concerning anemia, treatment data and iron status were recorded. RESULTS: C.E.R.A. achieved a good control of anemia in both naïve patients (mean Hemoglobin 11.6g/dL) and patients converted from a previous ESA (mean Hemoglobin 11.7g/dL). Most naïve patients received C.E.R.A. once monthly during the correction phase and required a low monthly dose (median dose 75 µg/month). The same median dose was required in patients converted from a previous ESA, and it was lower than recommended in the Summary of Product Characteristics (SPC). Iron status was adequate in 75% of anemic CKD patients, but only 50% of anemic patients with iron deficiency received iron supplementation. CONCLUSIONS: C.E.R.A. corrects and maintains stable hemoglobin levels in anemic CKD patients not on dialysis, requiring conversion doses lower than those recommended by the SPC, and achieving target hemoglobin levels with once-monthly dosing frequency both in naïve and converted patients.
|
Authors | Alberto Martínez-Castelao, Aleix Cases, Elisabeth Coll, Jordi Bonal, Josep M Galceran, Joan Fort, Francesc Moreso, Vicente Torregrosa, Lluís Guirado, Pilar Ruiz, Investigators of the Micenas II study |
Journal | Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia
(Nefrologia)
Vol. 35
Issue 1
Pg. 80-6
( 2015)
ISSN: 1989-2284 [Electronic] Spain |
PMID | 25349927
(Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hemoglobins
- continuous erythropoietin receptor activator
- Erythropoietin
- Polyethylene Glycols
- Iron
|
Topics |
- Adolescent
- Adult
- Aged
- Anemia
(etiology, prevention & control)
- Anemia, Iron-Deficiency
(blood, drug therapy, etiology)
- Diabetic Nephropathies
(blood)
- Drug Administration Schedule
- Erythropoietin
(administration & dosage, therapeutic use)
- Female
- Hemoglobins
(analysis)
- Humans
- Iron
(blood)
- Male
- Middle Aged
- Polyethylene Glycols
(administration & dosage, therapeutic use)
- Renal Insufficiency, Chronic
(blood, complications)
- Retrospective Studies
- Young Adult
|